drugset / Trial / NCT04161898

A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)

NCT04161898

Phase 3 Active not recruiting 56 enrolled AbbVie
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main objective of this study is to evaluate the efficacy of upadacitinib in combination with a corticosteroid taper regimen compared to placebo in combination with a corticosteroid taper regimen.

Timeline

Start
2020-02-04
Primary completion
2028-08
Completion
2028-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Upadacitinib Small molecule Oral
Background Prednisolone Other / unclassified Oral

Indications